Your browser doesn't support javascript.
loading
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Ramasamy, Karthik; Nooka, Ajay; Quach, Hang; Htut, Myo; Popat, Rakesh; Liedtke, Michaela; Tuchman, Sascha A; Laubach, Jacob; Gasparetto, Cristina; Chanan-Khan, Asher; Hertzberg, Mark; deMario, Mark; Nueesch, Eveline; Chesne, Evelyne; Franjkovic, Izolda; Lechner, Katharina; Kornacker, Martin; Cho, Hearn Jay.
Afiliación
  • Ramasamy K; Department of Haematology, Oxford University Hospital, NHS Trust, Oxford, United Kingdom. Karthik.ramasamy@ndcls.ox.ac.uk.
  • Nooka A; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Quach H; University of Melbourne, St. Vincent's Hospital, Fitzroy, VIC, Australia.
  • Htut M; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Popat R; University College London Hospitals, NHS Foundation Trust, London, United Kingdom.
  • Liedtke M; Stanford University Cancer Center, Stanford, CA, USA.
  • Tuchman SA; Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Laubach J; Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Newton, MA, USA.
  • Gasparetto C; Department of Medicine, Duke Univ. Medical Center, Durham, NC, USA.
  • Chanan-Khan A; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA.
  • Hertzberg M; Department of Clinical Haematology, Prince of Wales Hospital, Sydney, NSW, Australia.
  • deMario M; Roche Pharma Research and Early Development, New York, NY, USA.
  • Nueesch E; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
  • Chesne E; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
  • Franjkovic I; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.
  • Lechner K; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.
  • Kornacker M; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
  • Cho HJ; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Blood Cancer J ; 11(9): 149, 2021 09 03.
Article en En | MEDLINE | ID: mdl-34480019
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Tiadiazinas / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Cancer J Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Tiadiazinas / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Cancer J Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido